Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) CEO Taylor Schreiber bought 36,500 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The stock was bought at an average price of $1.21 per share, with a total value of $44,165.00. Following the transaction, the chief executive officer now directly owns 71,002 shares in the company, valued at $85,912.42. This represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shattuck Labs Trading Up 11.5 %
NASDAQ:STTK opened at $1.26 on Wednesday. Shattuck Labs, Inc. has a twelve month low of $1.07 and a twelve month high of $11.76. The company has a 50-day moving average of $3.30 and a 200-day moving average of $5.85. The firm has a market cap of $59.91 million, a price-to-earnings ratio of -0.68 and a beta of 1.72.
Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The firm had revenue of $1.61 million for the quarter, compared to analysts' expectations of $0.50 million. The firm's revenue was up 704.5% compared to the same quarter last year. On average, research analysts forecast that Shattuck Labs, Inc. will post -1.56 earnings per share for the current year.
Institutional Trading of Shattuck Labs
War on Elon Escalates…
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in Shattuck Labs by 4.8% during the first quarter. SG Americas Securities LLC now owns 39,377 shares of the company's stock valued at $352,000 after buying an additional 1,788 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Shattuck Labs by 8.5% during the second quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company's stock valued at $266,000 after buying an additional 5,397 shares in the last quarter. American Century Companies Inc. lifted its stake in Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company's stock valued at $183,000 after buying an additional 9,608 shares in the last quarter. Cannon Global Investment Management LLC purchased a new stake in Shattuck Labs during the first quarter valued at about $91,000. Finally, Virtu Financial LLC purchased a new stake in Shattuck Labs during the first quarter valued at about $113,000. 58.74% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the stock. Needham & Company LLC lowered shares of Shattuck Labs from a "buy" rating to a "hold" rating and set a $8.00 target price for the company. in a research report on Wednesday, October 2nd. BTIG Research lowered shares of Shattuck Labs from a "buy" rating to a "neutral" rating in a research report on Monday, June 17th. Citigroup lowered shares of Shattuck Labs from a "buy" rating to a "neutral" rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Evercore ISI upgraded shares of Shattuck Labs to a "strong-buy" rating in a research report on Wednesday, October 2nd. Finally, HC Wainwright lowered shares of Shattuck Labs from a "buy" rating to a "neutral" rating in a research report on Tuesday, October 1st. Four investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $8.67.
Check Out Our Latest Analysis on STTK
About Shattuck Labs
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
